Deutsche Bank analyst George Hill raised the firm’s price target on Cardinal Health to $88 from $77 and keeps a Hold rating on the shares. The analyst now sees an "increasing chance" that Cardinal is able to execute its planned turnaround of its medical segment. However, the firm admits to possibly missing the opportunity on the turnaround in Cardinal shares, saying the stock has already priced in the segment’s recovery before the results have been delivered.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CAH:
- GeneDx appoints Devin Schaffer as general counsel
- Cardinal Health initiated with a Neutral at Citi
- Cardinal Health exploring possible sale of nuclear medicine unit, Bloomberg says
- Cardinal Health price target lowered to $77 from $82 at Deutsche Bank
- Cardinal Health, Signify Health collaborate on in-home health management
